Martin Marietta Materials... (MLM)

MLM gains ground as its Quikrete deal sharpens focus on aggregates and injects $450M in cash for future growth.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Palvella's QTORIN rapamycin is its main value driver. This candidate is in Phase 3 trials for mLM. Management anticipates its top-line data by Q1 2026, with a potential NDA planned by 2H2026. If appro...

Martin Marietta Materials, Inc. (NYSE:MLM ) Analyst/Investor Day September 3, 2025 9:00 AM EDT Company Participants Jacklyn Rooker - Director of Investor Relations C. Nye - Chairman, CEO & President O...

Dividend hikes from CHMG, MTB, MLM and UCB stand out as investors seek stability amid Fed rate-cut uncertainty and market volatility.

Federal infrastructure spending should help the Zacks Building Products - Concrete & Aggregates industry players like VMC and MLM. Yet, high rates and expenses are risks.

A quiet wave is poised to capture the stock market's attention, having already done so for government officials and select traders who are well-informed about developments before they become headline ...

MLM's Q2 EPS rose 14% and beat estimates, while revenues missed slightly; 2025 guidance has been revised with higher EBITDA targets.

Martin Marietta Materials, Inc. (NYSE:MLM ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants C. Howard Nye - Chairman, CEO & President Jacklyn Rooker - Director of Inve...

The headline numbers for Martin Marietta (MLM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street es...